Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

Rhea-AI Summary

Clarus Therapeutics has appointed Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova brings nearly 30 years of experience in the pharmaceutical and biotech industry, previously leading clinical programs at Insmed and Pfizer. Her leadership is expected to enhance the clinical development of Clarus’ androgen and metabolic therapy pipeline, including potential orphan indications. Clarus aims to address unmet medical needs, with its first product being JATENZO, a testosterone therapy.

Positive

• Appointment of Zhanna Jumadilova as Chief Clinical Development Officer.
• Dr. Jumadilova has 30 years of experience in pharmaceutical and biotech sectors.
• Her leadership expected to advance Clarus' pipeline development.
• Focus on androgen and metabolic therapies with potential orphan indications.

Negative

• None.

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience

NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs at Insmed and Pfizer.

“Zhanna joins Clarus at a transformative time in our history as we further the clinical development of our pipeline assets,” said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. “With her proven leadership and extensive expertise in drug development, along with her ability to navigate global regulatory environments, Zhanna will be a tremendous asset as we progress Clarus’ pipeline. We welcome her to Clarus’ senior management team.”

“I am thrilled to be joining Clarus with its diverse pipeline of androgen and metabolic therapies for men and women, including several assets with potential orphan indications,” said Dr. Jumadilova. “I look forward to working with this dedicated team of experts and applying my own expertise to lead the company’s clinical development efforts to bring new medicines to patients in need.”

Prior to joining Clarus, Dr. Jumadilova served as Vice President, Clinical Development Head, ALIS at Insmed, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, where she focused on the development of Amikacin Liposome Inhalation Suspension (ALIS) for the treatment of adults with treatment-refractory Nontuberculous Mycobacterial (NTM) lung disease caused by Mycobacterium avium Complex (MAC). Prior to Insmed, Dr. Jumadilova worked at Pfizer for 15 years, where she served in leadership roles of increasing responsibility, and led clinical development programs and registrations for multiple small molecule and biosimilar compounds in urology, oncology, and inflammation. Earlier in her career, Dr. Jumadilova served in Medical Affairs and Health Economics and Outcomes Research roles for Schering-Plough (acquired by Merck), having begun her pharmaceutical career as a General Manager for Zeneca (now AstraZeneca). Prior to joining the industry, Dr. Jumadilova spent several years in academia.

Dr. Jumadilova received her M.D. degree from Kazakh State Medical University followed by a fellowship in Clinical Immunology. She also holds an M.B.A. from the Joseph M. Katz Graduate School of Business, University of Pittsburgh. Dr. Jumadilova has authored or co-authored numerous articles published in peer-reviewed medical journals.

About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO^® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

JATENZO^® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Investor Relations Contact:
Kara Stancell
kstancell@clarustherapeutics.com
(847) 562-4300 x 206

FAQ

What is the significance of Zhanna Jumadilova's appointment at Clarus Therapeutics?

Zhanna Jumadilova's appointment as Chief Clinical Development Officer is significant as she brings extensive experience and leadership that can enhance the clinical development of Clarus' pipeline, particularly for androgen and metabolic therapies.

What experience does Zhanna Jumadilova have before joining Clarus?

Before joining Clarus, Dr. Jumadilova led clinical development programs at Insmed and Pfizer, focusing on unmet medical needs and drug development.

What is the main focus of Clarus Therapeutics?

Clarus Therapeutics focuses on developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications.

What is JATENZO, and why is it important for Clarus?

JATENZO is Clarus Therapeutics' first commercial product, a testosterone therapy, crucial for addressing unmet medical needs in hormone replacement.

What potential impact does Dr. Jumadilova's expertise have on Clarus' future?

Dr. Jumadilova's expertise in navigating global regulatory environments and drug development could accelerate the progress of Clarus' clinical pipeline, potentially leading to new therapies for patients.